Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared...

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...